I. U1053 and B. Research, Team 3 oncogenesis of cutaneous lymphomas, Translational Oncology

D. Department, C. Lille, A. , and H. M. Hospital, Dermatology Department, Hospital Saint-Louis, Dermatology Department Dermatology Department, vol.10, issue.11

D. Department, . Chu-nantes-dermatology, . Department, C. Chu-grenoble, . Bordeaux et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling, Dermatology Department, CHU Reims Nature, vol.14, issue.403, pp.503-511, 2000.

E. Bessell, C. Humber, S. O-'connor, J. English, W. Perkins et al., Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification, British Journal of Dermatology, vol.143, issue.5, pp.1118-1123, 2012.
DOI : 10.1001/archderm.143.9.1144

E. Bohers, S. Mareschal, P. Bertrand, P. J. Viailly, S. Dubois et al., Activating somatic mutations in diffuse large B-cell lymphomas: lessons from next generation sequencing and key elements in the precision medicine era, Leukemia & Lymphoma, vol.122, issue.5, pp.1213-1222, 2015.
DOI : 10.1016/j.jmoldx.2012.11.006

L. Brenner, R. D. Arbeit, and T. Sullivan, IMO-8400, an Antagonist of Toll-like Receptors 7, 8, and 9, Development for Genetically Defined B-Cell Lymphomas: Safety and Activity in Phase 1 and Phase 2 Clinical Trials, p.3101, 2014.

A. A. Chanan-khan and B. D. Cheson, Lenalidomide for the Treatment of B-Cell Malignancies, Journal of Clinical Oncology, vol.26, issue.9, pp.1544-1552, 2008.
DOI : 10.1200/JCO.2007.14.5367

B. Coiffier, Rituximab therapy in malignant lymphoma, Oncogene, vol.94, issue.25, pp.3603-3613, 2007.
DOI : 10.1002/cncr.11511

B. Coiffier, E. Lepage, J. Briere, R. Herbrecht, H. Tilly et al., CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma, New England Journal of Medicine, vol.346, issue.4, pp.235-242, 2002.
DOI : 10.1056/NEJMoa011795

M. Compagno, W. K. Lim, A. Grunn, S. V. Nandula, M. Brahmachary et al., Mutations of multiple genes cause deregulation of NF-??B in diffuse large B-cell lymphoma, Nature, vol.272, issue.7247, pp.717-721, 2009.
DOI : 10.1038/nature07968

M. Czuczman, M. Trn?ný, and A. Davies, A Phase 2/3 multicenter, randomized study comparing the efficacy and safety of lenalidomide versus investigator's choice in relapsed/refractory DLBCL, Clin Cancer Res, 2017.

F. Davies and R. Baz, Lenalidomide mode of action: linking bench and clinical findings Long-term disease control in multiple myeloma: the impact of the dual mechanism of action of lenalidomide 24, Blood Rev, pp.13-19, 2010.

R. E. Davis, V. N. Ngo, G. Lenz, P. Tolar, R. Young et al., Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma, Chronic Active B Cell Receptor Signaling in Diffuse Large B Cell Lymphoma, pp.88-92, 2010.
DOI : 10.4049/jimmunol.166.3.1507

K. Dunleavy, S. Pittaluga, M. S. Czuczman, S. S. Dave, G. Wright et al., Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma, Blood, vol.113, issue.24, pp.6069-6076, 2009.
DOI : 10.1182/blood-2009-01-199679

C. Fang, D. Zhu, H. Dong, M. Ji, J. Wu et al., Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis, Int. J. Clin. Exp. Med, vol.8, pp.10705-10713, 2015.

P. Feugier, A. Van-hoof, C. Sebban, P. Solal-celigny, R. Bouabdallah et al., Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.23, issue.18, pp.4117-4126, 2005.
DOI : 10.1200/JCO.2005.09.131

I. W. Flinn, N. L. Bartlett, K. A. Blum, K. M. Ardeshna, A. S. Lacasce et al., A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), European Journal of Cancer, vol.54, pp.11-17, 2016.
DOI : 10.1016/j.ejca.2015.10.005

L. Fontan, C. Yang, V. Kabaleeswaran, L. Volpon, M. J. Osborne et al., MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In??Vitro and In??Vivo, MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo, pp.812-824, 2012.
DOI : 10.1016/j.ccr.2012.11.003

I. M. Ghobrial, A. Roccaro, F. Hong, E. Weller, N. Rubin et al., Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia, Clinical Cancer Research, vol.16, issue.3, pp.1033-1041, 2010.
DOI : 10.1158/1078-0432.CCR-09-1837

F. Grange, E. Maubec, and M. Bagot, Treatment of Cutaneous B-Cell Lymphoma, Leg Type, With Age-Adapted Combinations of Chemotherapies and Rituximab, Archives of Dermatology, vol.145, issue.3, pp.329-330, 2009.
DOI : 10.1001/archdermatol.2009.23

F. Grange and F. Antonicelli, Cutaneous Lymphomas, Archives of Dermatology, vol.145, issue.6, 2009.
DOI : 10.1001/archdermatol.2009.117

URL : https://hal.archives-ouvertes.fr/hal-00396446

F. Grange, M. W. Bekkenk, J. Wechsler, C. J. Meijer, L. Cerroni et al., Prognostic Factors in Primary Cutaneous Large B-Cell Lymphomas: A European Multicenter Study, Journal of Clinical Oncology, vol.19, issue.16, pp.3602-3610, 2001.
DOI : 10.1200/JCO.2001.19.16.3602

F. Grange, M. Beylot-barry, P. Courville, E. Maubec, M. Bagot et al., Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Archives of Dermatology, vol.143, issue.9, pp.1144-1150, 2007.
DOI : 10.1001/archderm.143.9.1144

F. Grange, M. D-'incan, N. Ortonne, S. Dalac, L. Laroche et al., Prise en charge des lymphomes B cutan??s??: recommandations du Groupe fran??ais d?????tude des lymphomes cutan??s, Annales de Dermatologie et de V??n??r??ologie, vol.137, issue.8-9, pp.523-531, 2010.
DOI : 10.1016/j.annder.2010.04.016

F. Grange, P. Joly, C. Barbe, M. Bagot, S. Dalle et al., Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France, JAMA Dermatology, vol.150, issue.5, pp.535-541, 2014.
DOI : 10.1001/jamadermatol.2013.7452

F. Grange, P. Joly, C. Barbe, M. Bagot, S. Dalle et al., Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France, JAMA Dermatology, vol.150, issue.5, pp.535-541, 2014.
DOI : 10.1001/jamadermatol.2013.7452

J. G. Gribben, N. Fowler, and F. Morschhauser, Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma, Journal of Clinical Oncology, vol.33, issue.25, pp.2803-2811, 2015.
DOI : 10.1200/JCO.2014.59.5363

E. Gupta, J. Accurso, J. Sluzevich, D. M. Menke, and H. W. Tun, Excellent outcome of immunomodulation or Bruton???s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type, Rare Tumors, vol.7, issue.4, pp.6067-2015, 2015.
DOI : 10.4081/rt.2015.6067

A. Guyot, N. Ortonne, L. Valeyrie-allanore, and M. Bagot, Combined treatment with rituximab and anthracycline-containing chemotherapy for primary cutaneous large Bcell lymphomas, leg type, in elderly patients, Arch. Dermatol, vol.146, pp.89-91, 2010.

C. Hallermann, C. Niermann, R. Fischer, and H. Schulze, Survival Data for 299 Patients with Primary Cutaneous Lymphomas: A Monocentre Study, Acta Dermato Venereologica, vol.91, issue.5, pp.521-525, 2011.
DOI : 10.2340/00015555-1112

C. P. Hans, D. D. Weisenburger, T. C. Greiner, R. D. Gascoyne, J. Delabie et al., Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray, Blood, vol.103, issue.1, pp.275-282, 2004.
DOI : 10.1182/blood-2003-05-1545

Y. Hao, B. Chapuy, S. Monti, H. H. Sun, S. J. Rodig et al., Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo, Clinical Cancer Research, vol.20, issue.10, pp.2674-2683, 2014.
DOI : 10.1158/1078-0432.CCR-13-3007

F. J. Hernandez-ilizaliturri, G. Deeb, P. L. Zinzani, S. A. Pileri, F. Malik et al., Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype, Cancer, vol.13, issue.suppl 1, pp.5058-5066, 2011.
DOI : 10.1016/j.gde.2003.08.004

J. J. Hoefnagel, M. M. Mulder, E. Dreef, P. M. Jansen, S. T. Pals et al., Expression of B-cell transcription factors in primary cutaneous B-cell lymphoma, Modern Pathology, vol.19, issue.9, pp.1270-1276, 2006.
DOI : 10.4049/jimmunol.165.10.5462

B. Holkova, M. Kmieciak, P. Bose, V. Y. Yazbeck, P. M. Barr et al., Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas, Leukemia & Lymphoma, vol.122, issue.3, pp.635-643, 2016.
DOI : 10.1111/j.1600-0609.1996.tb01390.x

V. Ivanov, D. Coso, B. Chetaille, B. Esterni, D. Olive et al., Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, Leukemia & Lymphoma, vol.19, issue.1, pp.2508-2513, 2014.
DOI : 10.1002/cncr.26135

F. Jardin, Next generation sequencing and the management of diffuse large B-cell lymphoma: from whole exome analysis to targeted therapy, Discov. Med, vol.18, pp.51-65, 2014.

P. N. Kelly, D. L. Romero, Y. Yang, A. L. Shaffer, D. Chaudhary et al., Selective interleukin-1 receptor???associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy, The Journal of Experimental Medicine, vol.11, issue.13, pp.2189-2201, 2015.
DOI : 10.1016/j.ccr.2012.05.024

S. J. Kim, H. J. Kang, D. Shin, D. H. Yoon, K. Sakamoto et al., Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma, Blood, vol.124, p.4443, 2014.

Y. H. Kim, R. Willemze, N. Pimpinelli, S. Whittaker, E. A. Olsen et al., TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC), Blood, vol.110, issue.2, pp.479-484, 2007.
DOI : 10.1182/blood-2006-10-054601

U. Klein, S. Casola, G. Cattoretti, Q. Shen, M. Lia et al., Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination, Nature Immunology, vol.3, issue.7, pp.773-782, 2006.
DOI : 10.4049/jimmunol.172.9.5427

K. Kodama, C. Massone, A. Chott, D. Metze, H. Kerl et al., Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients, Blood, vol.106, issue.7, pp.2491-2497, 2005.
DOI : 10.1182/blood-2005-03-1175

L. Koens, W. H. Zoutman, P. Ngarmlertsirichai, G. K. Przybylski, P. Grabarczyk et al., Nuclear Factor-??B Pathway???Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.134, issue.1, pp.290-292, 2014.
DOI : 10.1038/jid.2013.265

W. Kraan, H. M. Horlings, M. Van-keimpema, E. J. Schilder-tol, M. E. Oud et al., High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites, Blood Cancer Journal, vol.120, issue.9, p.139, 2013.
DOI : 10.1182/blood-2011-11-390989

É. Laban, M. Beylot-barry, N. Ortonne, M. Battistella, A. Carlotti et al., Lymphoprolif??rations cutan??es??: proposition d???algorithmes diagnostiques ?? partir de l???exp??rience sur 2ans des r??seaux INCa (LYMPHOPATH et GFELC) sur 2760??lymphoprolif??rations cutan??es, Annales de Pathologie, vol.35, issue.2, pp.131-147, 2015.
DOI : 10.1016/j.annpat.2015.02.001

J. P. Leonard, R. R. Furman, and M. Coleman, Proteasome inhibition with bortezomib: A new therapeutic strategy for non-Hodgkin's lymphoma, International Journal of Cancer, vol.104, issue.5, pp.971-979, 2006.
DOI : 10.4049/jimmunol.171.1.88

M. Loiarro, V. Ruggiero, and C. Sette, Targeting the Toll-like Receptor, 2013.

A. Lopez-girona, D. Heintel, L. Zhang, D. Mendy, S. Gaidarova et al., Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response, British Journal of Haematology, vol.109, issue.4 Suppl. 4, pp.325-336, 2011.
DOI : 10.1182/blood-2006-07-038703

P. Mondello, N. Steiner, W. Willenbacher, S. Ferrero, P. Ghione et al., Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?, The Oncologist, vol.21, issue.9, pp.1107-1112, 2016.
DOI : 10.1634/theoncologist.2016-0103

V. N. Ngo, R. M. Young, R. Schmitz, S. Jhavar, W. Xiao et al., Oncogenically active MYD88 mutations in human lymphoma, Nature, vol.206, issue.7332, pp.115-119, 2011.
DOI : 10.1084/jem.20090528

G. S. Nowakowski, A. Chiappella, T. E. Witzig, M. Spina, R. D. Gascoyne et al., ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma, Future Oncology, vol.126, issue.23, pp.1553-1563, 2016.
DOI : 10.1200/JCO.2007.15.9277

G. S. Nowakowski, B. Laplant, W. R. Macon, C. B. Reeder, J. M. Foran et al., Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non???Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study, Journal of Clinical Oncology, vol.33, issue.3, pp.251-257, 2015.
DOI : 10.1200/JCO.2014.55.5714

L. Pasqualucci, V. Trifonov, G. Fabbri, J. Ma, D. Rossi et al., Analysis of the coding genome of diffuse large B-cell lymphoma, Nature Genetics, vol.96, issue.9, pp.830-837, 2011.
DOI : 10.1093/bioinformatics/btl646

J. Paul, M. Soujon, A. M. Wengner, S. Zitzmann-kolbe, A. Sturz et al., Simultaneous Inhibition of PI3K?? and PI3K?? Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-??B and AKT, Simultaneous Inhibition of PI3K? and PI3K? Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-?B and AKT, pp.64-78, 2017.
DOI : 10.1016/j.ccell.2016.12.003

F. Peyrade, F. Jardin, C. Thieblemont, A. Thyss, J. Emile et al., Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial, The Lancet Oncology, vol.12, issue.5, pp.460-468, 2011.
DOI : 10.1016/S1470-2045(11)70069-9

A. Pham-ledard, M. Beylot-barry, and C. Barbe, High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type, JAMA Dermatology, vol.150, issue.11, pp.1173-1179, 2014.
DOI : 10.1001/jamadermatol.2014.821

A. Pham-ledard, D. Cappellen, F. Martinez, B. Vergier, M. Beylot-barry et al., MYD88 Somatic Mutation Is a Genetic Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.132, issue.8, pp.2118-2120, 2012.
DOI : 10.1038/jid.2012.102

A. Pham-ledard, A. Cowppli-bony, A. Doussau, M. Prochazkova-carlotti, E. Laharanne et al., Diagnostic and Prognostic Value of BCL2 Rearrangement in 53 Patients With Follicular Lymphoma Presenting as Primary Skin Lesions, American Journal of Clinical Pathology, vol.143, issue.3, pp.362-373, 2015.
DOI : 10.1309/AJCP4SUBR4NPSPTN

A. Pham-ledard, M. Prochazkova-carlotti, L. Andrique, D. Cappellen, B. Vergier et al., Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma, Modern Pathology, vol.32, pp.402-411, 2014.
DOI : 10.1097/DAD.0b013e3181c1195b

A. Pham-ledard, M. Prochazkova-carlotti, B. Vergier, T. Petrella, F. Grange et al., IRF4 Expression without IRF4 Rearrangement Is a General Feature of Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.130, issue.5, pp.1470-1472, 2010.
DOI : 10.1038/jid.2009.418

M. Roschewski, L. M. Staudt, and W. H. Wilson, Diffuse large B-cell lymphoma???treatment approaches in the molecular era, Nature Reviews Clinical Oncology, vol.120, issue.1, pp.12-23, 2013.
DOI : 10.1038/nature09671

P. Savini, A. Lanzi, F. G. Foschi, G. Marano, and G. F. Stefanini, Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type, Annals of Hematology, vol.22, issue.7, 2014.
DOI : 10.1093/annonc/mdq626

N. J. Senff, J. J. Hoefnagel, P. M. Jansen, M. H. Vermeer, J. Baarlen et al., Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO???EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers, Journal of Clinical Oncology, vol.25, issue.12, pp.1581-1587, 2007.
DOI : 10.1200/JCO.2006.09.6396

N. J. Senff, E. M. Noordijk, Y. H. Kim, M. Bagot, E. Berti et al., European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas, Blood, vol.112, issue.5, pp.1600-1609, 2008.
DOI : 10.1182/blood-2008-04-152850

N. J. Senff and R. Willemze, The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and S??zary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group, British Journal of Dermatology, vol.19, issue.6, pp.1205-1211, 2007.
DOI : 10.1182/blood-2005-03-1175

N. J. Senff, W. H. Zoutman, M. H. Vermeer, C. Assaf, E. Berti et al., Fine-Mapping Chromosomal Loss at 9p21: Correlation with Prognosis in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Journal of Investigative Dermatology, vol.129, issue.5, pp.1149-1155, 2009.
DOI : 10.1038/jid.2008.357

S. M. Smith, K. Van-besien, T. Karrison, J. Dancey, P. Mclaughlin et al., Temsirolimus Has Activity in Non???Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium, Journal of Clinical Oncology, vol.28, issue.31, pp.4740-4746, 2010.
DOI : 10.1200/JCO.2010.29.2813

U. Sundram, Y. Kim, S. Mraz-gernhard, R. Hoppe, Y. Natkunam et al., Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study, Journal of Cutaneous Pathology, vol.90, issue.3, pp.227-234, 2005.
DOI : 10.1111/j.1365-2133.2003.05649.x

A. Swaika, D. M. Menke, M. K. Jain, and T. Sher, Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type, Annals of Hematology, vol.93, issue.5, pp.895-896, 2014.
DOI : 10.1007/s00277-013-1787-0

S. H. Swerdlow, E. Campo, S. A. Pileri, N. L. Harris, H. Stein et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, vol.127, issue.20, pp.2375-2390, 2016.
DOI : 10.1182/blood-2016-01-643569

S. Swerdlow, E. Campo, L. Harris, and N. , WHO classification of tumours of haematopoietic and ymphoid tissues, 2008.

S. Tan, D. Machin, B. Tai, K. Foo, and E. Tan, A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer, British Journal of Cancer, vol.50, issue.6, pp.843-850, 2002.
DOI : 10.1038/sj.bjc.6600199

H. Tilly, M. Gomes-da-silva, U. Vitolo, A. Jack, M. Meignan et al., Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.116-125, 2015.
DOI : 10.1093/annonc/mdv304

S. P. Treon, L. Xu, G. Yang, Y. Zhou, X. Liu et al., MYD88 L265P Somatic Mutation in Waldenstr??m's Macroglobulinemia, MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia, pp.826-833, 2012.
DOI : 10.1056/NEJMoa1200710

D. Verhelle, L. G. Corral, K. Wong, J. H. Mueller, L. M. Parseval et al., Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells, Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells, pp.746-755, 2007.
DOI : 10.1158/0008-5472.CAN-06-2317

M. H. Vermeer, F. A. Geelen, C. W. Van-haselen, P. C. Van-voorst-vader, M. L. Geerts et al., Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group, Archives of Dermatology, vol.132, issue.11, pp.1304-1308, 1996.
DOI : 10.1001/archderm.132.11.1304

U. Vitolo, A. Chiappella, S. Franceschetti, A. M. Carella, I. Baldi et al., Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial, The Lancet Oncology, vol.15, issue.7, pp.730-737, 2014.
DOI : 10.1016/S1470-2045(14)70191-3

J. Q. Wang, Y. S. Jeelall, B. Beutler, K. Horikawa, and C. C. Goodnow, somatic mutation for B cell tolerance, The Journal of Experimental Medicine, vol.2013, issue.3, pp.413-426, 2014.
DOI : 10.1182/blood-2012-09-454355

M. Wang, N. Fowler, N. Wagner-bartak, L. Feng, J. Romaguera et al., Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial, Leukemia, vol.22, issue.9, pp.1902-1909, 2013.
DOI : 10.1200/JCO.2005.05.1003

T. Wang, L. Jia, W. Liao, L. Chen, X. Chen et al., [Primary cutaneous diffuse large B-cell lymphoma, leg type: a study of clinicopathology, immunophenotype and gene rearrangement], Zhonghua Bing Li Xue Za Zhi, vol.44, pp.100-105, 2015.

P. H. Wiernik, I. S. Lossos, J. M. Tuscano, G. Justice, J. M. Vose et al., Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma, Journal of Clinical Oncology, vol.26, issue.30, pp.4952-4957, 2008.
DOI : 10.1200/JCO.2007.15.3429

R. Willemze, E. S. Jaffe, G. Burg, L. Cerroni, E. Berti et al., WHO-EORTC classification for cutaneous lymphomas, .J.L.M., 2005. WHO-EORTC classification for cutaneous lymphomas, pp.3768-3785
DOI : 10.1182/blood-2004-09-3502

R. Willemze, H. Kerl, W. Sterry, E. Berti, L. Cerroni et al., EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer, Blood, vol.90, pp.354-371, 1997.

W. H. Wilson, R. M. Young, R. Schmitz, Y. Yang, S. Pittaluga et al., Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, .M., Staudt, L.M., 2015. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma, pp.922-926
DOI : 10.1200/JCO.2006.09.2403

T. E. Witzig, J. M. Vose, P. L. Zinzani, C. B. Reeder, R. Buckstein et al., An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma, Annals of Oncology, vol.22, issue.7, pp.1622-1627, 2011.
DOI : 10.1093/annonc/mdq626

Y. Yang, A. L. Shaffer, N. C. Emre, M. Ceribelli, M. Zhang et al., Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma, Cancer Cell, vol.21, issue.6, pp.723-737
DOI : 10.1016/j.ccr.2012.05.024

L. Zhang, J. Kosek, M. Wang, C. Heise, P. H. Schafer et al., Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression, British Journal of Haematology, vol.118, issue.Suppl. 1, pp.487-502, 2013.
DOI : 10.1182/blood-2011-05-356063

P. L. Zinzani, C. Pellegrini, L. Gandolfi, V. Stefoni, F. Quirini et al., Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial, Clinical Lymphoma Myeloma and Leukemia, vol.11, issue.6, pp.462-466, 2011.
DOI : 10.1016/j.clml.2011.02.001

P. L. Zinzani, P. Quaglino, N. Pimpinelli, E. Berti, G. Baliva et al., Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas, Journal of Clinical Oncology, vol.24, issue.9, pp.1376-1382, 2006.
DOI : 10.1200/JCO.2005.03.6285

P. L. Zinzani, L. Rigacci, M. C. Cox, L. Devizzi, A. Fabbri et al., Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice, Leukemia & Lymphoma, vol.17, issue.6, pp.1671-1676
DOI : 10.1111/bjh.12008

P. L. Zinzani, L. Rigacci, M. C. Cox, L. Devizzi, A. Fabbri et al., The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study, Leukemia & Lymphoma, vol.18, issue.1, pp.226-229, 2017.
DOI : 10.1002/cncr.28405

C. Bordeaux, Pôle"de"Santé"PubliqueUnité"de"Soutien"Méthodologique"à"la"Recherche"clinique"et"EpidémiologiqueService"de"Dermatologie

. Inserm-"-u1053 and . Bordeaux, Research"in"Translational"OncologyOncogénèse"des"lymphomes"cutanés' " 4 "Groupe"Français"d'étude"des"lymphomes"cutanés

@. Selon, inefficace'sur'les'19'patients'recrutés'mais'avec'un'manque'de'puissance'important.'Selon'l'approche'bayésienne,' même'avec'un'a"priori'optimiste'sur'l'efficacité'du'traitement,'l'intervalle'de'crédibilité'n'est'pas'strictement'supérieur'à'20%'après'avoir'pris'en'compte'les'données'de'l'essai.' ? Ces'deux'approches'tendent'vers'la'même'conclusion'd'efficacité'insuffisante'du'traitement.' ? En'l'absence'de'données'de'la'littérature'sur'ce'traitement'dans'des'populations'comparables,'l'analyse'bayésienne'a'permis'd'interpréter'les'résultats'suivant'différents'contextes' et'il'a'été'possible'd'utiliser'les'hypothèses'du'calcul'de'la'taille'd'étude'pour'définir'les'distributions'a'priori

'. R. Simon, Optimal'two5stage'designs'for'phase'II'clinical'trials, Control"Clin"Trials', vol.10, issue.1, pp.1-10, 1989.

. Zohar-'s,-'teramukai-'s,-'zhou-'y, Bayesian'design'and'conduct'of'phase'II'single5arm'clinical'trials'with'binary'outcomes:'a'tutorial, Contemp"Clin"Trials.', vol.29, pp.608-624, 2008.

. Tan-'sb,-'machin-'d and . Tai-'bc, A'Bayesian're5assessment'of'two'phase'II'trials'of'gemcitabine'in'metastatic'nasopharyngeal'cancer, Br"J"Cancer', vol.86, pp.843-50, 2002.